Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
13
×
drugs
13
×
fda
13
×
life sciences
national blog main
national top stories
clinical trials
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
boston
cancer
eli lilly
alnylam pharmaceuticals
astrazeneca
celgene
cystic fibrosis
gene therapy
investing
merck
What
fda
drug
medicine
bio
new
roundup
alnylam
approved
make
rna
week
ago
approval
big
companies
decades
disease
drugs
europe
interference
known
medical
meeting
oks
pharmaceuticals
rnai
second
time
uses
way
ahead
alzheimer’s
american
annual
approve
approves
arguments
asco
ash
assessed
Language
unknown
Current search:
fda
×
drugs
×
" boston top stories "
×
@xconomy.com
4 years ago
Jeff Leiden, Who Shaped Vertex Into a CF Force, to Switch Roles
@xconomy.com
4 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
ASH 2018: Three Up, Two Down As The Big Blood Disease Meeting Rolls On
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision